Letrozole Versus TP-Letrozole Regimen in the Treatment for Postmenopausal Women with Advanced Breast Cancer
HU Ping,CHEN Ping,BIAN Wei-gang(Yancheng First Hospital of Jiangsu Province,Yancheng 224021,China)
[Purpose]To compare the efficacy and safety of letrozole and TP-letrozole regimen in the treatment for postmenopausal advanced breast cancer.[Methods]Forty-seven cases with postmenopausal women with advanced breat cancer were randomized divided into two groups:23 patients with letrozole 2.5mg once daily,for 30 days as one cycle(group A),24 with two cycles of TP(docetaxel plus cisplatin)combination chemotherapy followed by letrozole same as group A(group B).[Results]The response rate was 39.1% in group A and 41.7% in group B(P0.05),and the clinical beneficial rates was 69.6% and 70.8% respectively(P0.05).There were no significant difference in efficacy between two groups with different receptor status,and menopausal status(P0.05).Group B is superior to group A in efficacy for visceral metastasis(P0.01).Median time to progression(mTTP)and duration of response in group A and B were 6.5 months vs.7.5 months and 9.6 months vs.11.6 months respectively(P0.05).The main side effects in two groups were Ⅰ～Ⅱdegree digestive tract toxicity,myclosuppression and hypodynamia.[Conclusions]Letrzole and TP-letrozole regimens are safe and effective and could be considered as a first line treatment for postmenopausal advanced breast cancer.TP-letrozole regimen maybe the first choice for visceral metastasis patient.